Targeting reperfusion injury in acute myocardial infarction: A review of reperfusion injury pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 8, 2012, Pages 1153-1175

  Sharma, Vikram ^a   Bell, Robert M ^a   Yellon, Derek M ^a  

^a Hatter Cardiovascular Institute   (United Kingdom)

Author keywords

Acute myocardial infarction; Cardioprotection; Lethal myocardial ischemia; Pharmacotherapy; Primary percutaneous coronary intervention; Reperfusion injury; Risk pathway; STEMI; Thrombolysis

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; CYCLOSPORIN; ERYTHROPOIETIN; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; INSULIN; METFORMIN; NICORANDIL; PLACEBO; POTASSIUM; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; TYROSINE KINASE RECEPTOR;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG INFUSION; DRUG MEGADOSE; DRUG TARGETING; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; LOW DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ANIMALS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

EID: 84861327442     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.685163     Document Type: Review

References (203)

1. World Health Organization. The Global burden of disease 2004 update. 2008
2. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116: 2634-53 (Pubitemid 350182388)
3. Herlitz J, Karlson BW, Hjalmarson A. Ten year mortality in relation to original size of myocardial infarct: results from the gothenburg metoprolol study. Br Heart J 1994;71: 238-41 (Pubitemid 24113528)
4. Herlitz J, Karlson BW, Hjalmarson A. Ten-year mortality rate after development of acute myocardial infarction in relation to clinical history and observations during hospital stay: experience from the goteborg metoprolol trial. Coron Artery Dis 1993;4: 1077-83 (Pubitemid 24055178)
5. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction. Circulation 2008;117: 296-329
6. Van de Werf F, Bax J, Betriu A, et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J2008;29: 2909-45
7. Kloner RA. Lethal 'Reperfusion injury': is it a real entity? J Thromb Thrombolysis 1997;4: 127-8 (Pubitemid 27087212)
8. Birnbaum Y, Leor J, Kloner RA. Pathobiology and clinical impact of reperfusion injury. J Thromb Thrombolysis 1995;2: 177-86
9. Jennings RB, Reimer KA. Acute myocardial ischemia: effects of reperfusion with arterial blood. Artif Cells Blood Substit Immobil Biotechnol 1994;22: 253-78 (Pubitemid 24202381)
10. Farb A, Kolodgie FD, Jenkins M, et al. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol 1993;21: 1245-53 (Pubitemid 23106204)
11. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21: 537-45 (Pubitemid 23047942)
12. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74: 1124-36 (Pubitemid 17174962)
13. Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 2005;289: H2-7 (Pubitemid 40934075)
14. van Vuuren D, Lochner A. Ischaemic postconditioning: from bench to bedside. Cardiovasc J Afr 2008;19: 311-20
15. Yetgin T, Manintveld OC, Duncker DJ, et al. Postconditioning against ischaemia-reperfusion injury: ready for wide application in patients? Neth Heart J 2010;18: 389-92
16. Li J, Xuan W, Yan R, et al. Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of beta-catenin. Clin Sci (Lond) 2011;120: 451-62
17. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as acomplement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375: 727-34
18. Venugopal V, Hausenloy DJ, Ludman A, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomized controlled trial. Heart 2009;95: 1567-71
19. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 2007;370: 575-9 (Pubitemid 47247853)
20. Andreka G, Vertesaljai M, Szantho G, et al. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart 2007;93: 749-52 (Pubitemid 46808282)
21. Kharbanda RK, Li J, Konstantinov IE, et al. Remote ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a preclinical study. Heart 2006;92: 1506-11 (Pubitemid 44578854)
22. Zhao ZQ. Postconditioning in reperfusion injury: a status report. Cardiovasc Drugs Ther 2010;24: 265-79
23. Gritsopoulos G, Iliodromitis EK, Zoga A, et al. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther 2009;23: 193-8
24. Li CM, Zhang XH, Ma XJ, et al. Limb ischemic postconditioning protects myocardium from ischemia-reperfusion injury. Scand Cardiovasc J2006;40: 312-17
25. Zhang XH, Li CM, Ma XJ, et al. Correlation of limb and myocardial ischemia postconditioning with acute myocardial reperfusion injury. Zhonghua Yi Xue Za Zhi 2006;86: 841-5
26. Kerendi F, Kin H, Halkos ME, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100: 404-12 (Pubitemid 41300495)
27. Reimer KA, Tanaka M, Murry CE, et al. Evaluation of free radical injury in myocardium. Toxicol Pathol 1990;18: 470-80
28. Richard VJ, Murry CE, Jennings RB, et al. Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications. Fundam Clin Pharmacol 1990;4: 85-103 (Pubitemid 20099932)
29. Kloner RA. Introduction to the role of oxygen radicals in myocardial ischemia and infarction. Free Radic Biol Med 1988;4: 5-7 (Pubitemid 18037801)
30. Jain AP, Mohan A, Gupta OP, et al. Role of oxygen free radicals in causing endothelial damage in acute myocardial infarction. J Assoc Physicians India 2000;48: 478-80
31. Kaljusto ML, Rutkovsky A, Stenslokken KO, et al. Postconditioning in mouse hearts is inhibited by blocking the reverse mode of the sodium-calcium exchanger. Interact Cardiovasc Thorac Surg 2010;10: 743-8
32. Blokhin IO, Vlasov TD, Galagudza MM, et al. Role of sodium-calcium exchanger in the myocardial protection against ischemia-reperfusion injury. Ross Fiziol Zh Im I M Sechenova 2008;94: 284-92
33. Wei GZ, Zhou JJ, Wang B, et al. Diastolic Ca2+ overload caused by Na+/Ca2+ exchanger during the first minutes of reperfusion results in continued myocardial stunning. Eur J Pharmacol 2007;572: 1-11 (Pubitemid 47374677)
34. Motegi K, Tanonaka K, Takenaga Y, et al. Preservation of mitochondrial function may contribute to cardioprotective effects of Na+/Ca2+ exchanger inhibitors in ischaemic/ reperfused rat hearts. Br J Pharmacol 2007;151: 963-78 (Pubitemid 47195536)
35. Imahashi K, Pott C, Goldhaber JI, et al. Cardiac-specific ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury. Circ Res 2005;97: 916-21 (Pubitemid 41552677)
36. Ryu SY, Peixoto PM, Teijido O, et al. Role of mitochondrial ion channels in cell death. Biofactors 2010;36: 255-63
37. Halestrap AP. Mitochondria and reperfusion injury of the heart - A holey death but not beyond salvation. J Bioenerg Biomembr 2009;41: 113-21
38. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53: 31-47 (Pubitemid 34020764)
39. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol 1989;21: 1241-51 (Pubitemid 20046099)
40. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 2010;3: 695-704
41. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking aRISK for cardioprotection. Heart Fail Rev 2007;12: 217-34 (Pubitemid 350176695)
42. Lacerda L, Somers S, Opie LH, et al. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009;84: 201-8
43. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 2009;47: 32-40
44. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61: 448-60 (Pubitemid 38210151)
45. Sivaraman V, Mudalagiri NR, Di Salvo C, et al. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol 2007;102: 453-9 (Pubitemid 47278818)
46. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005;15: 69-75 (Pubitemid 40693390)
47. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006;70: 240-53
48. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010;87: 406-23
49. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41: 508-15 (Pubitemid 36164511)
50. Davidson SM, Hausenloy D, Duchen MR, et al. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006;38: 414-19 (Pubitemid 41821888)
51. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010;38: 841-60
52. Kim M, Tian R. Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol 2011;51: 548-53
53. Russell RR III, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114: 495-503 (Pubitemid 39572099)
54. Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res 2003;42: 238-56 (Pubitemid 36411693)
55. Peralta C, Bartrons R, Serafin A, et al. Adenosine monophosphate- activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology 2001;34: 1164-73 (Pubitemid 33096589)
56. Gaskin FS, Kamada K, Yusof M, et al. 5-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am J Physiol Heart Circ Physiol 2007;292: H326-32 (Pubitemid 46105194)
57. Nishino Y, Miura T, Miki T, et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 2004;61: 610-19 (Pubitemid 38210166)
58. Sukhodub A, Jovanovic S, Du Q, et al. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K (+) channels. J Cell Physiol 2007;210: 224-36 (Pubitemid 44904718)
59. Matejikova J, Ravingerova T, Pancza D, et al. Mitochondrial KATP opening confers protection against lethal myocardial injury and ischaemia-induced arrhythmias in the rat heart via PI3K/Akt-dependent and -independent mechanisms. Can J Physiol Pharmacol 2009;87: 1055-62
60. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008;103: 203-15
61. Toombs CF, McGee DS, Johnston WE, et al. Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels. Cardiovasc Res 1993;27: 623-9 (Pubitemid 23144587)
62. Hill RJ, Oleynek JJ, Magee W, et al. Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol 1998;30: 579-85 (Pubitemid 28132735)
63. Sekili S, Jeroudi MO, Tang XL, et al. Effect of adenosine on myocardial 'stunning' in the dog. Circ Res 1995;76: 82-94
64. Cleveland JC Jr, Meldrum DR, Rowland RT, et al. Adenosine preconditioning of human myocardium is dependent upon the ATP-sensitive K+ channel. J Mol Cell Cardiol 1997;29: 175-82 (Pubitemid 27129141)
65. Norton ED, Jackson EK, Turner MB, et al. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J1992;123: 332-8
66. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24: 116-47 (Pubitemid 46696921)
67. Forman MB, Jackson EK. Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine. Clin Cardiol 2007;30: 583-5 (Pubitemid 350209970)
68. Pitarys CJ, Virmani R, Vildibill HD, et al. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991;83: 237-47
69. Cohen MV, Downey JM. Adenosine at reperfusion: a conundrum ready to be resolved. J Am Coll Cardiol 2009;53: 718-19
70. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996;31: 711-18 (Pubitemid 26175137)
71. Miyatake Y, Kusama Y, Kishida H, et al. Adenosine mediates the antiarrhythmic effect of ischemic preconditioning in isolated rat hearts. Jpn Circ J1996;60: 341-8
72. Miura T, Liu Y, Kita H, et al. Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 2000;35: 238-45 (Pubitemid 30061286)
73. Donato M, Morales C, D'Annunzio V, et al. The activation of A1 adenosine receptors attenuates myocardial stunning in the rabbit. Medicina (B Aires) 2001;61: 424-30 (Pubitemid 32861647)
74. Regan SE, Broad M, Byford AM, et al. A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity. Am JPhysiol Heart Circ Physiol 2003;284: H859-66 (Pubitemid 36228233)
75. Headrick JP, Gauthier NS, Morrison R, et al. Cardioprotection by K (ATP) channels in wild-type hearts and hearts overexpressing A (1)-adenosine receptors. Am J Physiol Heart Circ Physiol 2000;279: H1690-7
76. Lankford AR, Yang JN, Rose'Meyer R, et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2006;290: H1469-73
77. Baxter GF, Hale SL, Miki T, et al. Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14: 607-14 (Pubitemid 32217183)
78. Todd J, Zhao ZQ, Williams MW, et al. Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann Thorac Surg 1996;62: 1364-72 (Pubitemid 26383533)
79. Morrison RR, Tan XL, Ledent C, et al. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am JPhysiol Heart Circ Physiol 2007;293: H2523-9 (Pubitemid 47605899)
80. Methner C, Schmidt K, Cohen MV, et al. Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am JPhysiol Heart Circ Physiol 2010;299: H1262-4
81. Kis A, Baxter GF, Yellon DM. Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther 2003;17: 415-25 (Pubitemid 38339911)
82. Boucher M, Pesant S, Falcao S, et al. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. J Cardiovasc Pharmacol 2004;43: 416-22 (Pubitemid 38270609)
83. Kuno A, Solenkova NV, Solodushko V, et al. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008;295: H1288-95
84. Philipp S, Yang XM, Cui L, et al. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 2006;70: 308-14
85. Wan TC, Ge ZD, Tampo A, et al. The A3 adenosine receptor agonist CP-532,903 [N6- (2,5-dichlorobenzyl)-3- aminoadenosine-5c-Nmethylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther 2008;324: 234-43 (Pubitemid 350294150)
86. Maddock HL, Gardner NM, Khandoudi N, et al. Protection from myocardial stunning by ischaemia and hypoxia with the adenosine A3 receptor agonist, IB-MECA. Eur J Pharmacol 2003;477: 235-45 (Pubitemid 38366396)
87. Auchampach JA, Rizvi A, Qiu Y, et al. Selective activation of A3 adenosine receptors with N6- (3-iodobenzyl) adenosine-5c-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80: 800-9 (Pubitemid 27230054)
88. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of amulticenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34: 1711-20
89. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J2006;27: 2400-5 (Pubitemid 44522145)
90. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 2003;59: 1-9 (Pubitemid 36702752)
91. Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am JCardiovasc Drugs 2004;4: 159-67 (Pubitemid 38780002)
92. Sakuma T, Motoda C, Tokuyama T, et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol 2010;140: 200-9
93. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J2003;146: 146-52 (Pubitemid 36851314)
94. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011;32: 867-77
95. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2011;107: 1131-5
96. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004;94: 9-13 (Pubitemid 38813445)
97. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101: 2154-9 (Pubitemid 30253043)
98. Bose AK, Mocanu MM, Carr RD, et al.Glucagon-like peptide 1 can directly protect the heart against ischemia/ reperfusion injury. Diabetes 2005;54: 146-51 (Pubitemid 40105106)
99. Bose AK, Mocanu MM, Carr RD, et al. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as apreconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19: 9-11 (Pubitemid 40767767)
100. Hausenloy DJ, Yellon DM. GLP-1 therapy: beyond glucose control. Circ Heart Fail 2008;1: 147-9
101. Huisamen B, Genis A, Marais E, et al. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Drugs Ther 2011;25: 13-20
102. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109: 962-5 (Pubitemid 38282847)
103. Burger D, Xenocostas A, Feng QP. Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol 2009;2: 56-69
104. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100: 4802-6 (Pubitemid 36457809)
105. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J2004;18: 1031-3 (Pubitemid 39561515)
106. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108: 79-85 (Pubitemid 36859024)
107. Tamareille S, Ghaboura N, Treguer F, et al. Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 2009;297: H2035-43
108. Mudalagiri NR, Mocanu MM, Di Salvo C, et al. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol 2008;153: 50-6
109. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther 2005;19: 333-6 (Pubitemid 43029818)
110. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005;100: 397-403 (Pubitemid 41300494)
111. Lipsic E, van der MP, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/ reperfusion. J Cardiovasc Pharmacol 2004;44: 473-9 (Pubitemid 39305089)
112. Rafiee P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005;100: 187-97 (Pubitemid 41348809)
113. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45: 1406-12 (Pubitemid 40615610)
114. Binbrek AS, Rao NS, Al Khaja N, et al. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009;104: 1035-40
115. Suh JW, Chung WY, Kim YS, et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011;149: 216-20
116. Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is apromising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010;74: 1415-23
117. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010;74: 2365-71
118. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011;147: 124-31
119. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31: 2593-600
120. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomized controlled clinical trial. Heart 2011;97: 1560-5
121. Andreotti F, Agati L, Conti E, et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: new Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis 2009;28: 489-95
122. Baines CP, Wang L, Cohen MV, et al. Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 1999;94: 188-98 (Pubitemid 29329303)
123. Jonassen AK, Sack MN, Mjos OD, et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89: 1191-8 (Pubitemid 34627878)
124. Jonassen AK, Brar BK, Mjos OD, et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000;32: 757-64 (Pubitemid 30658913)
125. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003;41: 1404-7 (Pubitemid 36439004)
126. Ji L, Fu F, Zhang L, et al. Insulin attenuates myocardial ischemia/ reperfusion injury via reducing oxidative/nitrative stress. Am J Physiol Endocrinol Metab 2010;298: E871-80
127. Jonassen AK, Aasum E, Riemersma RA, et al. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000;14: 615-23 (Pubitemid 32217184)
128. Zhang HF, Fan Q, Qian XX, et al. Role of insulin in the anti-apoptotic effect of glucose-insulin-potassium in rabbits with acute myocardial ischemia and reperfusion. Apoptosis 2004;9: 777-83 (Pubitemid 40941206)
129. Zhu P, Lu L, Xu Y, et al. Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2000;278: H595-603 (Pubitemid 30131261)
130. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314: 1512-15 (Pubitemid 27216066)
131. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26: 650-61 (Pubitemid 40516876)
132. Aas AM, Ohrvik J, Malmberg K, et al. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes Obes Metab 2009;11: 323-9
133. Turel B, Gemici K, Baran I, et al. Effects of glucose-insulin-potassium solution added to reperfusion treatment in acute myocardial infarction. Anadolu Kardiyol Derg 2005;5: 90-4 (Pubitemid 40861921)
134. Zhang L, Zhang L, Li YH, et al. High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction. Eur J Clin Invest 2005;35: 164-70 (Pubitemid 40343881)
135. Yang YM, Zhu J, Tan HQ, et al. Effect of high dose glucose-insulin- potassium infusion in patients with acute ST-segment elevation myocardial infarction: analysis of 7510 patients in China as part of CREATE-ECLA study. Zhonghua Yi Xue Za Zhi 2008;88: 1806-10
136. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298: 2399-405 (Pubitemid 350190781)
137. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 2005;68: 8-17 (Pubitemid 41268613)
138. Chen BN, Rayner TE, Menadue MF, et al. Effect of ischaemia and role of eicosanoids in release of atrial natriuretic factor from rat heart. Cardiovasc Res 1993;27: 1576-9 (Pubitemid 23297520)
139. Zhang Y, Oliver JR, Horowitz JD. The role of endothelin in mediating ischemia/ hypoxia-induced atrial natriuretic peptiderelease. J Cardiovasc Pharmacol 2004;43: 227-33 (Pubitemid 38129681)
140. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006;69: 318-28 (Pubitemid 43098788)
141. Rose RA, Giles WR. Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol 2008;586: 353-66
142. Takata Y, Hirayama Y, Kiyomi S, et al. The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion. Cardiovasc Res 1996;32: 286-93 (Pubitemid 26246874)
143. Rastegar MA, Vegh A, Papp JG, et al. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs. Cardiovasc Drugs Ther 2000;14: 471-9
144. Okawa H, Horimoto H, Mieno S, et al. Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem 2003;248: 171-7 (Pubitemid 36833656)
145. Yang XM, Philipp S, Downey JM, et al. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006;101: 311-18 (Pubitemid 43923387)
146. Moalem J, Davidov T, Katz E, et al. Atrial natriuretic peptide reverses the negative functional effects of stunning in rabbit myocardium. Regul Pept 2005;132: 47-52 (Pubitemid 41607502)
147. Sangawa K, Nakanishi K, Ishino K, et al. Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 2004;77: 233-7 (Pubitemid 38130016)
148. Wakui S. Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery. Ann Thorac Cardiovasc Surg 2005;11: 12-20
149. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370: 1483-93 (Pubitemid 47625560)
150. Kasama S, Furuya M, Toyama T, et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J2008;29: 1485-94 (Pubitemid 351890353)
151. Kuga H, Ogawa K, Oida A, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 2003;67: 443-8 (Pubitemid 36554068)
152. Efthymiou CA, Mocanu MM, Yellon DM. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 2005;45: 247-52 (Pubitemid 40328147)
153. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005;45: 1287-91
154. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003;41: 649-56 (Pubitemid 36373804)
155. Jones SP, Gibson MF, Rimmer DM III, et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002;40: 1172-8
156. Joyce M, Kelly CJ, Chen G, et al. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur JVasc Endovasc Surg 2001;21: 295-300 (Pubitemid 32529994)
157. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100: 178-84 (Pubitemid 29330017)
158. Liu YH, Zhang M, Liu LM, et al. Effects and potential mechanisms of short-term use of simvastatin on myocardial no-reflow after ischemia-reperfusion in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36: 729-34
159. Szarszoi O, Maly J, Ostadal P, et al. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol Res 2008;57: 793-6
160. Vilahur G, Casani L, Pena E, et al. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009;206: 95-101
161. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in amodel of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit 2003;9: BR155-9 (Pubitemid 36713428)
162. Wolfrum S, Dendorfer A, Schutt M, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3- kinase/Akt pathway. J Cardiovasc Pharmacol 2004;44: 348-55 (Pubitemid 39129454)
163. Matetzky S, Fefer P, Shenkman B, et al. Statins have an early antiplatelet effect in patients with acute myocardial infarction. Platelets 2011;22: 103-10
164. Ludman A, Venugopal V, Yellon DM, et al. Statins and cardioprotection: more than just lipid lowering? Pharmacol Ther 2009;122: 30-43
165. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3: 332-9
166. Hong YJ, Jeong MH, Hyun DW, et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005;95: 619-22 (Pubitemid 40255252)
167. Kiyokuni M, Kosuge M, Ebina T, et al.Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy. Circ J2009;73: 330-5
168. Garot P, Bendaoud N, Lefevre T, et al. Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock. EuroIntervention 2010;6: 350-5
169. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110: 674-8 (Pubitemid 39056265)
170. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49: 1272-8 (Pubitemid 46467240)
171. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54: 558-65
172. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54: 2157-63
173. Das B, Sarkar C, Karanth KS. Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/ reperfusion-induced arrhythmias and infarct size in anesthetized rabbits. Naunyn Schmiedebergs Arch Pharmacol 2001;364: 383-96 (Pubitemid 33020816)
174. Sanada S, Kitakaze M, Asanuma H, et al. Role of mitochondrial and sarcolemmal K (ATP) channels in ischemic preconditioning of the canine heart. Am J Physiol Heart Circ Physiol 2001;280: H256-63
175. Menasche P, Kevelaitis E, Mouas C, et al. Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection? J Thorac Cardiovasc Surg 1995;110: 1606-13
176. Vegh A, Gyorgyi K, Papp JG, et al. Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia. Eur J Pharmacol 1996;305: 163-8 (Pubitemid 26195991)
177. Takarabe K, Okazaki Y, Higuchi S, et al. Nicorandil attenuates reperfusion injury after long cardioplegic arrest. Asian Cardiovasc Thorac Ann 2007;15: 204-9 (Pubitemid 47023515)
178. Iwai T, Tanonaka K, Motegi K, et al. Nicorandil preserves mitochondrial function during ischemia in perfused rat heart. Eur J Pharmacol 2002;446: 119-27 (Pubitemid 34722565)
179. Watzinger N, Lund GK, Higgins CB, et al. Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction. Cardiovasc Res 2002;54: 77-84
180. Imagawa J, Baxter GF, Yellon DM. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 1998;31: 74-9 (Pubitemid 28027901)
181. Das B, Sarkar C. Mitochondrial K ATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model. Pharmacol Res 2003;47: 447-61 (Pubitemid 36542923)
182. Das B, Sarkar C. Cardiomyocyte mitochondrial KATP channels participate in the antiarrhythmic and antiinfarct effects of KATP activators during ischemia and reperfusion in an intact anesthetized rabbit model. Pol J Pharmacol 2003;55: 771-86 (Pubitemid 37540877)
183. Yasu T, Ikeda N, Ishizuka N, et al. Nicorandil and leukocyte activation. J Cardiovasc Pharmacol 2002;40: 684-92 (Pubitemid 36109286)
184. Carreira RS, Monteiro P, Kowaltowski AJ, et al. Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion. J Bioenerg Biomembr 2008;40: 95-102
185. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005;112: 1284-8 (Pubitemid 41266722)
186. Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J 2008;72: 1425-9
187. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J2004;68: 928-32 (Pubitemid 39419487)
188. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33: 654-60
189. Hausenloy DJ, Maddock HL, Baxter GF, et al. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002;55: 534-43 (Pubitemid 34874948)
190. Squadrito F, Altavilla D, Squadrito G, et al. Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Eur J Pharmacol 1999;364: 159-68 (Pubitemid 29065266)
191. Weinbrenner C, Liu GS, Downey JM, et al. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc Res 1998;38: 678-84
192. Mathieu P, Bendavid Y, Buluran J, et al. Cyclosporine A prevents ischemia-reperfusion induced myocardial dysfunction in the isolated heart of the rat. Ann Chir 1997;51: 912-18 (Pubitemid 27483517)
193. Griffiths ES, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusioninduced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25: 1461-9 (Pubitemid 24049454)
194. Gogvadze V, Richter C. Cyclosporine A protects mitochondria in an in vitro model of hypoxia/reperfusion injury. FEBS Lett 1993;333: 334-8 (Pubitemid 23324011)
195. Oka N, Wang L, Mi W, et al. Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 2008;135: 123-30
196. Chavez E, Garcia N, Pavon N. Inhibition of permeability transition and myocardic reperfusion damage by cyclosporine A. Arch Cardiol Mex 2007;77 (Suppl 4): S4-81
197. Xie JR, Yu LN. Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion. Acta Anaesthesiol Scand 2007;51: 909-13
198. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005;38: 367-74 (Pubitemid 40215206)
199. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359: 473-81
200. Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55: 1200-5
201. Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: the hatter workshop recommendations. Basic Res Cardiol 2010;105: 677-86
202. Schwartz LL, Kloner RA, Arai AE, et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 2011;124: 1172-9
203. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37: 1820-6 (Pubitemid 32499965)